AU8054391A - Novel, protracted insulin analogues - Google Patents

Novel, protracted insulin analogues

Info

Publication number
AU8054391A
AU8054391A AU80543/91A AU8054391A AU8054391A AU 8054391 A AU8054391 A AU 8054391A AU 80543/91 A AU80543/91 A AU 80543/91A AU 8054391 A AU8054391 A AU 8054391A AU 8054391 A AU8054391 A AU 8054391A
Authority
AU
Australia
Prior art keywords
novel
insulin analogues
protracted insulin
protracted
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU80543/91A
Inventor
Liselotte Langkjaer
Jan Markussen
Kjeld Norris
Leo Boye Snel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU8054391A publication Critical patent/AU8054391A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU80543/91A 1990-06-28 1991-06-21 Novel, protracted insulin analogues Abandoned AU8054391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK155690A DK155690D0 (en) 1990-06-28 1990-06-28 NEW PEPTIDES
DK1556/90 1990-06-28

Publications (1)

Publication Number Publication Date
AU8054391A true AU8054391A (en) 1992-01-23

Family

ID=8106031

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80543/91A Abandoned AU8054391A (en) 1990-06-28 1991-06-21 Novel, protracted insulin analogues

Country Status (10)

Country Link
EP (1) EP0536245A1 (en)
JP (1) JPH05508406A (en)
AU (1) AU8054391A (en)
DK (1) DK155690D0 (en)
IE (1) IE912247A1 (en)
IL (1) IL98596A0 (en)
NZ (1) NZ238718A (en)
PT (1) PT98124A (en)
WO (1) WO1992000321A1 (en)
ZA (1) ZA914830B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
JP3872105B2 (en) * 1995-03-17 2007-01-24 ノボ ノルディスク アクティーゼルスカブ Insulin derivative
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
ATE550041T1 (en) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease resistant insulin analogues
JP5496082B2 (en) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein
EP2229407B1 (en) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Novel insulin derivatives having an extremely delayed time-action profile
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
HUE037449T2 (en) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102008064270A1 (en) * 2008-12-20 2010-07-01 Voith Patent Gmbh Flotation method for removing contaminants from aqueous fibrous material suspension by gas bubbles, involves supplying stream of fibrous material suspension along interference body after supplying stream of gas
JP5735960B2 (en) 2009-07-06 2015-06-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin preparations containing methionine
TW201113032A (en) 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
WO2011003820A1 (en) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
RU2556340C2 (en) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Long-acting insulin composition
AR080669A1 (en) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST, AN INSULIN AND METIONIN
WO2011058082A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
CN102933599A (en) * 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 Human insulin containing additional disulfide bonds
EP2585484A1 (en) * 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
CN103533952B (en) * 2011-03-15 2017-02-15 诺沃—诺迪斯克有限公司 Human insulin analogues and derivatives comprising cysteine substitutions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (en) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland pharmaceutical combination for use in glycemic control in type 2 diabetes patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 glycosylation isoforms
MX360420B (en) 2012-12-19 2018-10-31 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof.
WO2014102623A1 (en) 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201601477VA (en) 2013-09-30 2016-04-28 Wockhardt Ltd Pharmaceutical composition
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899190B (en) 2014-01-09 2022-06-14 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
PL3229828T3 (en) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
HRP20221324T1 (en) 2016-12-16 2022-12-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US11857608B2 (en) 2017-03-09 2024-01-02 Diamedica Inc. Dosage forms of tissue kallikrein 1
CN111032685A (en) 2017-08-17 2020-04-17 诺沃挪第克公司 Novel acylated insulin analogues and uses thereof
CN109646396A (en) * 2018-12-29 2019-04-19 江苏万邦医药科技有限公司 A kind of stable insulin analog injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (en) * 1975-08-13 1977-02-24 Hoechst Ag Prolonged action insulin analogues - with A1-glycine replaced by D-alanine or D-serine
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (en) * 1988-05-11 1988-05-11 Novo Industri As NEW PEPTIDES
KR910700262A (en) * 1988-12-23 1991-03-14 안네 제케르 Human insulin analogues

Also Published As

Publication number Publication date
DK155690D0 (en) 1990-06-28
ZA914830B (en) 1992-03-25
IL98596A0 (en) 1992-07-15
WO1992000321A1 (en) 1992-01-09
NZ238718A (en) 1992-06-25
IE912247A1 (en) 1992-01-01
EP0536245A1 (en) 1993-04-14
PT98124A (en) 1992-04-30
JPH05508406A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
AU8054391A (en) Novel, protracted insulin analogues
AU566321B1 (en) N,n1-dihalo-2-imidazolidinones
AU3151689A (en) Improved cryo-slammer
AU5732890A (en) Heart-assist balloon pump
AU2980689A (en) Methanol
AU6784587A (en) Thieno-1,4-diazepines
AU4714789A (en) Cyclic ether derivatives
AU8414891A (en) Epoxidation catalysts
AU2868789A (en) 1,4-disubstituted-piperidinyl compounds
AU4109689A (en) Cyclic grf-analogs ii
AU4726789A (en) Polycarbonate composition.
AU3233589A (en) Latching mechanism
AU9128891A (en) Single use syringe
AU7374387A (en) 2-hydrazono-4,6-dinitrobenthiazolones
AU2368892A (en) Igf-ii analogues
AU5504690A (en) Sequential parity correction
AU4918790A (en) Medicament
AU4511489A (en) 14alpha,17alpha-ethano-estratrienes
AU8008091A (en) Insulin analogues with organ preferential action
AU1959488A (en) (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonin
AU8799291A (en) Improved antenna structure
AU649061B2 (en) Single use syringe
AU6309890A (en) Stabilized leukocyte-interferons
AU3113389A (en) Fungicidal imidazolylmethyloxiranes
AU6494790A (en) Cyclic voltammetry